HDAC Inhibitors in Hematological and Solid Tumor Therapy: Current Success, Challenges, and Future Directions

Area of Science:

• Oncology
• Epigenetics
• Pharmacology

Background:

• Abnormal histone deacetylase (HDAC) activity is linked to cancer development by disrupting cellular processes and suppressing tumor suppressor genes.
• HDAC inhibitors are emerging as key epigenetic regulators for treating both hematological malignancies and solid tumors.

Purpose of the Study:

• To comprehensively review the molecular diversity of HDAC inhibitors across various cancer types.
• To analyze their efficacy in hematological versus solid tumors, considering existing pharmacokinetic limitations.
• To explore novel combination therapies and isoform-specific inhibitors for enhanced cancer treatment.

Main Methods:

• Examination of DNA methylation, histone modification, and miRNA regulation in response to HDAC inhibitors.
• Analysis of differential efficacy in hematological and solid tumors.
• Review of combination strategies with targeted therapies and immunotherapeutics.

Main Results:

• HDAC inhibitors alter epigenetic landscapes, showing established efficacy in hematological tumors but facing pharmacokinetic challenges in solid tumors.
• Combination therapies, including with targeted medicines and immunotherapeutics, demonstrate synergistic effects.
• Selective inhibitors targeting specific HDAC isoforms (e.g., HDAC6, HDAC11) show potential for metabolically active tumors.

Conclusions:

• Development of more selective HDAC inhibitors with improved pharmacokinetics is crucial.
• Optimizing combination strategies is essential for personalized cancer treatment.
• Addressing resistance mechanisms and improving solid tumor delivery are key challenges for future therapeutic advancements.